Aripiprazole added to antidepressants for psychotic depression
About this title
Read the official source — NCT00556140Researchers studied Aripiprazole, tracking side effects to assess safety and tolerability in people with depression.
Understand this study
What did researchers investigate?
Researchers studied Aripiprazole, tracking side effects to assess safety and tolerability in people with depression.
Who was this study for?
Listed age limits: 18 years to 80 years.
What did participation involve?
The study group receives aripiprazole as a study medication.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 80 Years
- Official registry ID
- NCT00556140
- Official title
Show the full official title
The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Boston
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Aripiprazole, tracking side effects to assess safety and tolerability in people with depression.
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 18 years to 80 years.
